Aclaris Therapeutics (NASDAQ:ACRS) Sees Large Volume Increase
Aclaris Therapeutics (NASDAQ:ACRS) Sees Large Volume Increase
Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) shares saw unusually-strong trading volume on Friday . Approximately 758,008 shares traded hands during mid-day trading, an increase of 107% from the previous session's volume of 366,400 shares.The stock last traded at $17.30 and had previously closed at $16.82.
周五，Aclaris治疗公司(纳斯达克代码：ACRS-GET评级)的股票交易量异常强劲。午盘交易中，约有758,008股易手，较前一交易日的366,400股增加107%。该股最新报17.30美元，此前收盘报16.82美元。
Analysts Set New Price Targets
分析师设定新的价格目标
A number of analysts have weighed in on ACRS shares. Stifel Nicolaus started coverage on Aclaris Therapeutics in a research report on Tuesday, December 13th. They issued a "buy" rating and a $29.00 price target for the company. The Goldman Sachs Group started coverage on Aclaris Therapeutics in a research report on Thursday, December 1st. They issued a "buy" rating and a $25.00 price target for the company. SVB Leerink reaffirmed an "outperform" rating on shares of Aclaris Therapeutics in a research report on Tuesday, November 8th. BTIG Research assumed coverage on Aclaris Therapeutics in a research report on Thursday, October 6th. They issued a "buy" rating and a $32.00 price target for the company. Finally, StockNews.com assumed coverage on Aclaris Therapeutics in a research report on Wednesday, October 12th. They set a "sell" rating for the company. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $28.67.
许多分析师都加入了ACRS的股票。Stifel Nicolaus于12月13日星期二在一份研究报告中开始报道Aclaris治疗公司。他们对该公司的评级为“买入”，目标价为29.00美元。高盛在12月1日星期四的一份研究报告中开始对Aclaris治疗公司进行报道。他们对该公司的评级为“买入”，目标价为25美元。SVB Leerink在11月8日(星期二)的一份研究报告中重申了对Aclaris治疗公司股票的“跑赢大盘”评级。BTIG Research在10月6日星期四的一份研究报告中承担了对Aclaris治疗公司的报道。他们对该公司的评级为买入，目标价为32.00美元。最后，StockNews.com在10月12日星期三的一份研究报告中承担了对Aclaris治疗公司的报道。他们为该公司设定了“卖出”评级。一名投资分析师对该股的评级为卖出，六名分析师对该公司的评级为买入。根据MarketBeat的数据，该股目前的共识评级为“适度买入”，共识目标价为28.67美元。
Aclaris Therapeutics Trading Up 3.9 %
Aclaris治疗公司股价上涨3.9%
The firm has a market cap of $1.17 billion, a price-to-earnings ratio of -13.55 and a beta of 0.53. The firm has a 50-day moving average of $16.24 and a two-hundred day moving average of $16.06.
该公司的市值为11.7亿美元，市盈率为-13.55，贝塔系数为0.53。该公司的50日移动均线切入位16.24美元，200日移动均线切入位16.06美元。
Insider Transactions at Aclaris Therapeutics
Aclaris治疗公司的内幕交易
In other news, insider Joseph Monahan sold 5,000 shares of Aclaris Therapeutics stock in a transaction that occurred on Thursday, December 15th. The stock was sold at an average price of $15.88, for a total transaction of $79,400.00. Following the sale, the insider now owns 96,386 shares of the company's stock, valued at approximately $1,530,609.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Aclaris Therapeutics news, Director Neal Walker sold 25,000 shares of Aclaris Therapeutics stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $15.25, for a total transaction of $381,250.00. Following the sale, the director now owns 1,220,763 shares in the company, valued at $18,616,635.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Joseph Monahan sold 5,000 shares of Aclaris Therapeutics stock in a transaction on Thursday, December 15th. The stock was sold at an average price of $15.88, for a total transaction of $79,400.00. Following the sale, the insider now owns 96,386 shares in the company, valued at approximately $1,530,609.68. The disclosure for this sale can be found here. 6.70% of the stock is owned by insiders.
在其他消息方面，内部人士约瑟夫·莫纳汉在12月15日星期四的一笔交易中出售了5,000股Aclaris治疗公司的股票。该股以15.88美元的平均价格出售，总成交金额为79,400.00美元。出售后，这位内部人士现在拥有该公司96,386股股票，价值约1,530,609.68美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可通过美国证券交易委员会网站。在Aclaris治疗公司的其他消息方面，董事尼尔·沃克在1月3日(星期二)的一笔交易中出售了25,000股Aclaris治疗公司的股票。这些股票以15.25美元的平均价格出售，总成交额为381,250.00美元。交易完成后，董事现在拥有该公司1220,763股股份，价值18,616,635.75美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可以通过这个环节。此外，内部人士约瑟夫·莫纳汉在12月15日星期四的一笔交易中出售了5,000股Aclaris治疗公司的股票。该股以15.88美元的平均价格出售，总成交金额为79,400.00美元。出售后，这位内部人士现在拥有该公司96,386股，价值约1,530,609.68美元。关于这次销售的披露可以找到这里。6.70%的股份由内部人士持有。
Institutional Investors Weigh In On Aclaris Therapeutics
机构投资者看好Aclaris治疗公司
A number of institutional investors have recently bought and sold shares of the business. Wellington Management Group LLP boosted its stake in Aclaris Therapeutics by 3.4% during the first quarter. Wellington Management Group LLP now owns 5,730,253 shares of the biotechnology company's stock worth $98,789,000 after buying an additional 190,985 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Aclaris Therapeutics by 3.0% during the third quarter. BlackRock Inc. now owns 4,810,298 shares of the biotechnology company's stock valued at $75,714,000 after acquiring an additional 140,382 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Aclaris Therapeutics by 4.2% during the third quarter. Vanguard Group Inc. now owns 2,931,709 shares of the biotechnology company's stock valued at $46,145,000 after acquiring an additional 118,024 shares during the period. Commodore Capital LP lifted its holdings in shares of Aclaris Therapeutics by 4.1% during the second quarter. Commodore Capital LP now owns 2,410,622 shares of the biotechnology company's stock valued at $33,652,000 after acquiring an additional 95,974 shares during the period. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Aclaris Therapeutics by 6.9% during the third quarter. Point72 Asset Management L.P. now owns 1,853,251 shares of the biotechnology company's stock valued at $29,170,000 after acquiring an additional 119,351 shares during the period. Institutional investors and hedge funds own 95.33% of the company's stock.
一些机构投资者最近买卖了该公司的股票。惠灵顿管理集团LLP在第一季度将其在Aclaris治疗公司的股份增加了3.4%。惠灵顿管理集团(Wellington Management Group LLP)现在拥有这家生物技术公司5730,253股股票，价值98,789,000美元，上个季度又购买了190,985股。贝莱德股份有限公司在第三季度增持了Aclaris治疗公司的股票3.0%。贝莱德股份有限公司在此期间增持了140,382股，目前持有这家生物技术公司4,810,298股股票，价值75,714,000美元。先锋集团在第三季度增持了4.2%的Aclaris Treateutics股票。先锋集团目前持有这家生物技术公司2,931,709股股票，价值46,145,000美元，在此期间又收购了118,024股。Commodore Capital LP在第二季度增持了Aclaris Treeutics的股票4.1%。Commodore Capital LP现在拥有这家生物技术公司2,410,622股股票，价值33,652,000美元，在此期间又购买了95,974股。最后，Point72 Asset Management L.P.在第三季度增持了6.9%的Aclaris Treeutics股票。Point72 Asset Management L.P.在此期间额外收购了119,351股，现在拥有1,853,251股这家生物技术公司的股票，价值29,170,000美元。机构投资者和对冲基金持有该公司95.33%的股票。
About Aclaris Therapeutics
关于Aclaris Treeutics
(Get Rating)
(获取评级)
Aclaris Therapeutics, Inc operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.
Aclaris治疗公司经营着一家临床阶段的生物制药公司，在美国开发治疗免疫性炎症性疾病的新型候选药物。它通过两个部门运作：治疗和合同研究。治疗部门参与确定和开发创新疗法，以解决免疫炎症性疾病的重大未得到满足的需求。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Aclaris Therapeutics (ACRS)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- 免费获取StockNews.com关于Aclaris治疗公司(ACRS)的研究报告
- 市场回顾周-1/23-1/27
- 为什么Lucid在一天内飙升了近100%
- 利用这些铁路股票实现增长和收入
- ASML预计今年芯片需求回升，提振销售观点
- KLA公司：在动荡不安的半市场中站稳脚跟
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Aclaris治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Aclaris治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。